The European Commission (EC) granted a marketing authorization of IMRALDI®, an adalimumab biosimilar
Posted on26 Aug 2017
TagsAdalimumab, Anti TNF therapy, BENEPALI, Biogen, Biosimilar, FLIXABI, humira, IMRALDI, Samsung Bioepis
Comments0
The European Commission (EC) granted a marketing authorization for IMRALDI® (also known as SB5), an adalimumab biosimilar referencing Humira®. IMRALDI has been... Read More